New combo therapy aims to boost tumor control in pancreatic cancer

This early-phase study tests whether adding the drug fulvestrant to standard radiation therapy (Lu-DOTATATE) is safe and helps shrink tumors in people with advanced pancreatic neuroendocrine tumors. About 25 adults whose cancer has spread or cannot be removed by surgery will take part. The goal is to see if the combination works better than radiation alone.